Literature DB >> 16965191

A review of agitation in mental illness: treatment guidelines and current therapies.

Stephen R Marder1.   

Abstract

BACKGROUND: Agitation is an important therapeutic target in the acute and/or emergent setting, as well as for longer-term care of patients with psychiatric illness.
METHOD: Select reviews and guidelines published (from 2000 to 2006) on the treatment of agitation in various psychiatric disorders were evaluated.
RESULTS: After maximizing the safety of all individuals in the presence of an acutely agitated patient, initial therapy generally involves verbal deescalation. Pharmacologic management of acute agitation relies on typical antipsychotics, particularly haloperidol; benzodiazepines; and atypical antipsychotics. The selection of a specific agent (or combination of agents) should be guided by etiologic considerations, efficacy of the drug(s), side effects, potential drug interactions, and drug formulation. Seclusion or restraints are treatments of last resort due to safety issues.
CONCLUSION: Compared with conventional antipsychotics (e.g., haloperidol), preliminary evidence indicates that atypical antipsychotics effectively reduce agitation, are better tolerated, and have fewer side effects. After an acute episode, atypical agents also help ease the transition from intramuscular to oral medication to promote ongoing treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16965191

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  24 in total

1.  Diagnosing and managing violence.

Authors:  Jeffrey C Fetter
Journal:  Prim Care Companion CNS Disord       Date:  2011

2.  [Inhaled loxapine for emergency treatment of agitated patients with borderline personality disorder : A series of five cases].

Authors:  T H C Krüger; M A Wollmer; P Negt; H Frieling; S Jung; K G Kahl
Journal:  Nervenarzt       Date:  2016-11       Impact factor: 1.214

3.  Is there an alternative to seclusion or mechanical restraint?

Authors:  Branimir Margetić; Branka Aukst-Margetić; Adela Matusin
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

4.  Demographics, clinical characteristics, and treatment of aggressive patients admitted to the acute behavioral unit of a community general hospital: a prospective observational study.

Authors:  Rosemary Nourse; Cynthia Reade; Jill Stoltzfus; Vikrant Mittal
Journal:  Prim Care Companion CNS Disord       Date:  2014-06-05

Review 5.  Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia.

Authors:  Gillian M Keating
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

Review 6.  Management of patients presenting with acute psychotic episodes of schizophrenia.

Authors:  Pierre Thomas; Köksal Alptekin; Mihai Gheorghe; Mauro Mauri; José Manuel Olivares; Michael Riedel
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

7.  A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation.

Authors:  Theodore D Satterthwaite; Daniel H Wolf; Robert A Rosenheck; Raquel E Gur; Stanley N Caroff
Journal:  J Clin Psychiatry       Date:  2008-12-02       Impact factor: 4.384

8.  Effectiveness and medication acceptance of olanzapine disintegrating tablets compared to standard olanzapine tablets in acutely treated psychiatric patients.

Authors:  Jörg Czekalla; Thomas Wagner; Alexander Schacht; Michael Kluge; Bruce Kinon
Journal:  Patient Prefer Adherence       Date:  2007-12-20       Impact factor: 2.711

9.  "Coercion Experience Scale" (CES)--validation of a questionnaire on coercive measures.

Authors:  Jan Bergk; Erich Flammer; Tilman Steinert
Journal:  BMC Psychiatry       Date:  2010-01-14       Impact factor: 3.630

10.  Issues in the management of acute agitation: how much current guidelines consider safety?

Authors:  Bruno Pacciardi; Mauro Mauri; Claudio Cargioli; Simone Belli; Biagio Cotugno; Luca Di Paolo; Stefano Pini
Journal:  Front Psychiatry       Date:  2013-05-07       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.